Aug 27, 2024 - Taiwania Capital and Axil Capital are thrilled to announce the establishment and launch of TaiAx Life Science Fund L.P. (“TaiAx”), a pioneering venture capital fund dedicated to investing in transformative innovations within the life science sector. TaiAx Capital L.P., the GP of the fund, is an international joint venture between Taiwania Capital Management (“Taiwania”) based in Taipei and Axil Capital Group (“Axil”) based in Tokyo. This collaboration aims to leverage the unique strengths of both firms to unlock hidden value in startups worldwide. The target fund size is $200 million.

 

Led by a seasoned team of industry experts, TaiAx aims to catalyze breakthrough advancements in biotechnology, pharmaceuticals, medical devices, and healthcare technologies. Leveraging Taiwania and Axil’s diverse resources, the fund is poised to support early-stage startups and emerging companies that demonstrate exceptional potential to revolutionize healthcare and improve patient outcomes.

 

“Axil and Taiwania have been collaborating for several years and we are excited by this opportunity to continue our journey together,” said Fred Shane, Managing Partner of Axil. “We believe that our strategic approach, combined with our deep sector expertise, will not only drive financial success but also contribute significantly to advancing global health” said Jerome Shen, General Partner of Taiwania’s Bio Fund.

 

TaiAx will leverage its extensive network and strategic partnerships to provide portfolio companies with not only capital but also operational guidance, industry connections, and access to key resources necessary for growth and scalability.

 

The fund’s investment thesis focuses on areas such as rare diseases, gene and cell therapy, AI-driven medical devices, and first-in-class therapeutics, among others.  By supporting visionary entrepreneurs and disruptive technologies, TaiAx seeks to accelerate innovation cycles and bring life-changing therapies to market faster.

 

Notable backers of the TaiAx fund include the National Development Fund of the Executive Yuan, Mizuho Securities Co., Ltd., and Mega International Commercial Bank Co., Ltd.

 

For more information about TaiAx and its investment criteria, please visit Taiwania and Axil websites: https://en.taiwaniacapital.com/ and https://www.axilcapital.com/en

 

About Taiwania:  Taiwania Capital is a venture capital firm founded in August 2017 by the National Development Fund of the Executive Yuan along with private enterprises. As of now, Taiwania Capital manages 8 funds and focuses on investing in early to growth-stage technology and biotech startups in Taiwan, the U.S., Japan, Southeast Asia and Central East Europe. Its mission is to connect Taiwan's robust tech and biotech ecosystems with global innovations, providing resources to its portfolio companies to enhance their growth and market penetration.

About Axil:  Axil Capital is a venture capital firm based in Tokyo, Japan, specializing in investments within the biomedical and healthcare technology sectors. Founded in 2017 as a spin-out from Mizuho Securities, Axil Capital aims to foster synergies between the biotech ecosystems in Japan and the rest of the world. The firm invests across various stages, from seed to late-stage ventures, focusing on biopharmaceuticals, medical devices, digital health, and healthcare services.